Caring Brands, Inc. (NASDAQ:CABR) Short Interest Update

Caring Brands, Inc. (NASDAQ:CABR) was the target of a significant drop in short interest in the month of July. As of July 31st, there was short interest totaling 427 shares, a drop of 98.8% from the July 15th total of 36,455 shares. Based on an average trading volume of 41,414 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.0% of the shares of the company are sold short.

Caring Brands Trading Down 5.4%

Shares of NASDAQ:CABR opened at $1.39 on Thursday. The firm has a 50 day moving average price of $1.34. Caring Brands has a 12 month low of $0.71 and a 12 month high of $5.35. The company has a quick ratio of 5.62, a current ratio of 5.66 and a debt-to-equity ratio of 0.03. The firm has a market cap of $12.64 million and a PE ratio of -2.17.

Caring Brands (NASDAQ:CABR) last released its earnings results on Thursday, August 13th. The company reported ($0.10) earnings per share for the quarter.

Institutional Investors Weigh In On Caring Brands

An institutional investor recently bought a new stake in Caring Brands stock. Jane Street Group LLC bought a new position in Caring Brands, Inc. (NASDAQ:CABR) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 34,446 shares of the company’s stock, valued at approximately $30,000. Jane Street Group LLC owned approximately 0.25% of Caring Brands as of its most recent SEC filing.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Caring Brands from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 11th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Caring Brands currently has an average rating of “Sell”.

About Caring Brands

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability. Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team.